Autolus Therapeutics plc (AUTL)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 21.2M | 24.3M | 26.2M | 45.7M |
| Gross Profit | (7.4M) | (1.0M) | 1.6M | 25.2M |
| Operating Income | (71.6M) | (72.5M) | (59.5M) | (43.8M) |
| Net Income | (79.1M) | (90.3M) | (71.6M) | (39.1M) |
| Diluted EPS | $-0.30 | N/A | $-0.27 | $-0.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 6.2M | 1.7M | 10.1M | 75.4M |
| Gross Profit | 1.7M | (1.3M) | (21.0M) | |
| Operating Income | (142.9M) | (175.5M) | (241.4M) | (270.5M) |
| Net Income | (148.8M) | (208.4M) | (220.7M) | (287.5M) |
| Diluted EPS | $-1.57 | $-1.20 | $-0.86 | $-1.08 |